MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Sees Significant Increase in Short Interest

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) was the target of a significant growth in short interest in the month of December. As of December 15th, there was short interest totaling 1,685,137 shares, a growth of 144.9% from the November 30th total of 687,986 shares. Currently, 6.7% of the company’s stock are sold short. Based on an average daily trading volume, of 1,479,960 shares, the days-to-cover ratio is currently 1.1 days. Based on an average daily trading volume, of 1,479,960 shares, the days-to-cover ratio is currently 1.1 days. Currently, 6.7% of the company’s stock are sold short.

MAIA Biotechnology Stock Up 6.1%

MAIA traded up $0.09 during midday trading on Friday, hitting $1.57. 761,956 shares of the company traded hands, compared to its average volume of 977,358. The company’s 50-day moving average is $1.22 and its 200 day moving average is $1.50. MAIA Biotechnology has a 52 week low of $0.87 and a 52 week high of $2.74. The firm has a market capitalization of $58.14 million and a PE ratio of -2.15.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last issued its earnings results on Friday, November 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.08). On average, sell-side analysts predict that MAIA Biotechnology will post -1.3 earnings per share for the current fiscal year.

Insider Buying and Selling at MAIA Biotechnology

In related news, Director Stan Smith purchased 57,189 shares of the stock in a transaction dated Monday, December 22nd. The stock was purchased at an average price of $1.22 per share, with a total value of $69,770.58. Following the transaction, the director directly owned 1,421,478 shares in the company, valued at $1,734,203.16. This trade represents a 4.19% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Steven M. Chaouki purchased 40,849 shares of the company’s stock in a transaction that occurred on Monday, December 22nd. The stock was purchased at an average price of $1.22 per share, for a total transaction of $49,835.78. Following the purchase, the director owned 151,873 shares in the company, valued at $185,285.06. This represents a 36.79% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 368,352 shares of company stock valued at $427,192 in the last quarter. 32.32% of the stock is owned by insiders.

Institutional Investors Weigh In On MAIA Biotechnology

A number of large investors have recently made changes to their positions in MAIA. Centric Wealth Management grew its position in MAIA Biotechnology by 740.2% during the second quarter. Centric Wealth Management now owns 573,398 shares of the company’s stock valued at $1,032,000 after buying an additional 505,150 shares during the period. Geode Capital Management LLC increased its stake in shares of MAIA Biotechnology by 3.6% in the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock worth $400,000 after purchasing an additional 7,746 shares in the last quarter. Jane Street Group LLC bought a new position in MAIA Biotechnology in the 2nd quarter worth $52,000. Marshall Wace LLP purchased a new position in MAIA Biotechnology during the second quarter valued at $29,000. Finally, Centerpoint Advisory Group bought a new stake in MAIA Biotechnology during the second quarter valued at about $28,000. 5.65% of the stock is currently owned by institutional investors.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.